Succinylcholine: Difference between revisions
(adverse effects) |
User238345 (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
*Type: [[Neuromuscular blocker]] | *Type: [[Neuromuscular blocker]] | ||
*Dosage Forms: IV or IM | *Dosage Forms: IV or IM | ||
*Common Trade Names: | *Common Trade Names: Anectine; Quelicin; Quelicin-1000 | ||
==Adult Dosing== | ==Adult Dosing== | ||
Revision as of 04:23, 6 October 2015
See critical care quick reference for drug doses by weight.
General
- Type: Neuromuscular blocker
- Dosage Forms: IV or IM
- Common Trade Names: Anectine; Quelicin; Quelicin-1000
Adult Dosing
- 1.5 mg/kg IV
- 4 mg/kg IM (in extremis)
Pediatric Dosing
See critical care quick reference for drug doses by weight.
Special Populations
- Pregnancy Rating:
- Lactation:
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Contraindications
- Hyperkalemia
- Preexisting hyperkalemia
- Burns >5d old
- Crush injury >5d old
- Severe infection >5d old
- Neuromuscular diseases (e.g. Myasthenia Gravis), myopathies
- History of Malignant Hyperthermia
- Allergy to class/drug
Adverse Reactions
Serious
- Fatal hyperkalemia
- Malignant hyperthermia
- Masseter spasm
Common
Pharmacology
- Onset: 45-60 seconds
- Metabolism:
- Excretion:
- Mechanism of Action:
- Duration of Action: 5-10 minutes
See Also
Sources
- Levitan, R. Annals of EM. Vol 45, Issue 2. Safety of succinylcholine in myasthenia gravis.